Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14367864 | 0.82 | CA2 (0.55) | CA2LTA4H | |
| SCHEMBL10975283 | 0.74 | CA2 (0.51) | CA2ADRA1BADRA1ALTA4H | |
| SCHEMBL10975676 | 0.74 | CA2 (0.51) | CA2ADRA1BADRA1ALTA4H | |
| SCHEMBL14367866 | 0.72 | POLB (0.53) | CA2ADRA1BADRA1AHTR1A | |
| SCHEMBL6174128 | 0.72 | POLB (0.53) | CA2ADRA1BADRA1AHTR1A | |
| SCHEMBL14367881 | 0.72 | POLB (0.53) | CA2ADRA1BADRA1AHTR1A | |
| SCHEMBL10980854 | 0.71 | TSHR (0.52) | HTR1A | |
| SCHEMBL10980851 | 0.71 | TSHR (0.52) | HTR1A | |
| SCHEMBL10978073 | 0.71 | TSHR (0.52) | HTR1A | |
| SCHEMBL4622391 | 0.70 | TSHR (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835735-B2 | Anticancer, tyrosine kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-12-28 | — | — | US | disclosed |
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | KOREAN INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | EGFR, ERBB2, ERBB4 | CA2 1381/4885EGFR 1/4885ABCB1 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.